Formulation Design and Optimization for the Improvement of Nystatin-Loaded Lipid Intravenous Emulsion

被引:22
作者
Marin-Quintero, Deiry [1 ]
Fernandez-Campos, Francisco [1 ]
Calpena-Campmany, Ana C. [1 ]
Montes-Lopez, Maria J. [2 ]
Clares-Naveros, Beatriz [3 ]
Del Pozo-Carrascosa, Alfonso [1 ]
机构
[1] Univ Barcelona, Fac Pharm, Dept Pharm & Pharmaceut Technol, Barcelona, Spain
[2] Univ Barcelona, Fac Pharm, Dept Microbiol, Barcelona, Spain
[3] Univ Granada, Fac Pharm, Dept Pharm & Pharmaceut Technol, E-18071 Granada, Spain
关键词
drug design; nystatin; lipids; emulsion; injectables; surfactants; candida; aspergillus; mathematical model; IN-VITRO ACTIVITY; DELIVERY; EPIDEMIOLOGY; DISSOLUTION; STABILITY; RELEASE; SAFETY;
D O I
10.1002/jps.23711
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nystatin (NYS) is a polyene macrolide with broad antifungal spectrum restricted to topical use owing to its toxicity upon systemic administration. The aims of this work were the design, development, and optimization of NYS-loaded lipid emulsion for intravenous administration. A closed circuit system was designed to apply ultrasound during the elaboration of the lipid intravenous emulsions (LIEs). Additionally, a comparison with the commercially available Intralipid((R)) 20% was also performed. Manufacturing conditions were optimized by factorial design. Formulations were evaluated in terms of physicochemical parameters, stability, release profile, and antimicrobial activity. The average droplet size, polydispersity index, zeta-potential, pH, and volume distribution values ranged between 192.5 and 143.0nm, 0.170 and 0.135, -46 and -44mV, 7.11 and 7.53, 580 and 670nm, respectively. The selected NYS-loaded LIE (NYS-LIE54) consisted of soybean oil (30%), soybean lecithin (2%), solutol HS (R) 15 (4%), and glycerol (2.25%) was stable for at least 60 days. In vitro drug release studies of this formulation suggested a sustained-release profile. Equally, NYS-LIE54 showed the best antimicrobial activity being higher than the free drug. Thus, it could be a promising drug delivery system to treat systemic fungal infections. (c) 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:4015-4023, 2013
引用
收藏
页码:4015 / 4023
页数:9
相关论文
共 34 条
[1]  
[Anonymous], 1998, M38P NCCLS
[2]   In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates [J].
Arikan, S ;
Ostrosky-Zeichner, L ;
Lozano-Chiu, M ;
Paetznick, V ;
Gordon, D ;
Wallace, T ;
Rex, JH .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (04) :1406-1412
[3]   Molecular epidemiology of candidemia:: Evidence of clusters of smoldering nosocomial infections [J].
Asmundsdottir, Lena Ros ;
Erlendsdottir, Helga ;
Haraldsson, Gunnsteinn ;
Guo, Hong ;
Xu, Jianping ;
Gottfredsson, Magnus .
CLINICAL INFECTIOUS DISEASES, 2008, 47 (02) :E17-E24
[4]   Turbiscan Lab® Expert analysis of the stability of ethosomes® and ultradeformable liposomes containing a bilayer fluidizing agent [J].
Celia, Christian ;
Trapasso, Elena ;
Cosco, Donato ;
Paolino, Donatella ;
Fresta, Massimo .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2009, 72 (01) :155-160
[5]   Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133
[6]   Drug release from lipid liquid crystalline phases: relation with phase behavior [J].
Costa-Balogh, Fatima O. ;
Sparr, Emma ;
Simoes Sousa, Joao Jose ;
Pais, Alberto Canelas .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2010, 36 (04) :470-481
[7]   Cooperative partition model of nystatin interaction with phospholipid vesicles [J].
Coutinho, A ;
Prieto, M .
BIOPHYSICAL JOURNAL, 2003, 84 (05) :3061-3078
[8]   The effects of Pluronic block copolymers on the aggregation state of nystatin [J].
Croy, SR ;
Kwon, GS .
JOURNAL OF CONTROLLED RELEASE, 2004, 95 (02) :161-171
[9]   Lipid injectable emulsions: Pharmacopeial and safety issues [J].
Driscoll, David F. .
PHARMACEUTICAL RESEARCH, 2006, 23 (09) :1959-1969
[10]   Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin [J].
El-Ridy, Mohammed Shafik ;
Abdelbary, Ahmed ;
Essam, Tamer ;
Abd EL-Salam, Rania Mohsen ;
Kassem, Ahmed Alaa Aly .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2011, 37 (12) :1491-1508